Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.
- Circulating endothelial cells
- Circulating tumor cells
- Nab-paclitaxel bevacizumab
- Triple negative breast cancer
ASJC Scopus subject areas
- Cancer Research